Biotech BeiGene slides in Shanghai after $3.5 bln STAR debut

Cancer treatment specialist BeiGene Ltd plunged 16.4% on its Shanghai debut on Wednesday after raising $3.5 billion, hit by concerns over its valuation amid potential U.S. sanctions on Chinese biotech …
( read original story …)